PIERRE FABRE PHARMACEUTICALS RESUBMITS TABELECLEUCEL BIOLOGICS LICENSE APPLICATION FOR TREATMENT OF EPSTEIN-BARR VIRUS POSITIVE-POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE TO THE FDA

Reuters · 1d ago

Please log in to view news